Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma
NCT03338166 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2017-11-09
Summary
Hepatocellular carcinoma represents the commonest primary cancer of the liver.serum lactate dehydrogenase is an indirect marker of tumor hypoxia,angioneogenesis and worse prognosis.
Conditions
Interventions
- OTHER
-
LDH serum level
Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
Aml R Ibrahim, Lecturer · Assiut University
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-02
- Primary Completion
- 2018-07-31
- Completion
- 2018-12-31
More Related Trials
-
Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional Therapy
NCT01281683 ·Status: UNKNOWN
-
Assessment of Frailty in Patients With Advanced Hepatocellular Cancers
NCT02482259 ·Status: COMPLETED
-
The Utility of Cell-free Methylation Markers in Blood for Hepatocellular Carcinoma
NCT05576571 ·Status: UNKNOWN
-
Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits
NCT01937286 ·Status: COMPLETED
-
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
NCT03804593 ·Status: COMPLETED
-
Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma .
NCT06168357 ·Status: NOT_YET_RECRUITING
-
Liquid Biopsy in Hepatocellular Carcinoma
NCT04111029 ·Status: UNKNOWN
-
Frequency of Circulating Tumor Cells (CTCs) and Amount of Cell-free DNA (cfDNA) in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
NCT03162198 ·Status: COMPLETED
-
Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)
NCT05543304 ·Status: UNKNOWN
-
Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies
NCT05613621 ·Status: ACTIVE_NOT_RECRUITING
-
Prospective Cohort Study in Patients With NAFLD
NCT00575133 ·Status: RECRUITING
-
Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome"
NCT04616664 ·Status: COMPLETED
-
Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
NCT05887661 ·Status: RECRUITING ·Phase: NA
-
Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver
NCT02288910 ·Status: COMPLETED
-
Role of RDW as Anon Invasive Index for Predicting Liver Cell Failure and Portal Hypertension in Cirrhotic Patient
NCT03242135 ·Status: UNKNOWN
-
NAFLD in Patient of Hypothyroidism
NCT05813301 ·Status: NOT_YET_RECRUITING
-
To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma
NCT02074202 ·Status: UNKNOWN ·Phase: PHASE3
-
Novel Molecular Spectrometric Biomarkers in Blood Plasma as an Early Diagnostic Tool in HCC
NCT04221347 ·Status: UNKNOWN
-
Liver Diseases: Extracellular Vesicles as Biomarkers
NCT07185360 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Risk of Hepatocellular Carcinoma in Patient With Liver Cirrhosis
NCT03083002 ·Status: UNKNOWN
-
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI
NCT00154531 ·Status: UNKNOWN
-
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases
NCT01631318 ·Status: COMPLETED ·Phase: NA
-
Understanding Gene ENvironment Interaction in ALcohol-related Hepatocellular Carcinoma
NCT07272200 ·Status: RECRUITING ·Phase: NA
-
Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta
NCT02461966 ·Status: COMPLETED ·Phase: NA
-
Discrepancies in Management of Hepatocellualr Carcinoma Between Practice and Recommendations
NCT04189809 ·Status: UNKNOWN